Skip to content
FDA ApprovedGLP-1 / GIP✓ Free to read

Tirzepatide

Also called Mounjaro / Zepbound

A once-a-week shot that turns hunger down so hard the results rival weight-loss surgery.

Updated 19 May 2026Read 4 minBacked by 60 studies
The quick version
What it is
A weekly shot (copies GLP-1 and GIP)
Is it FDA-approved?
Yes, for weight loss and type 2 diabetes
How strong is the proof?
Very strong: big human studies
How you take it
A small shot under the skin, once a week
Typical result
About 22.5% of body weight lost
Biggest catch
Upset stomach early; weight returns if you stop

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

Tirzepatide is a medicine you inject once a week. You may know it by its brand names, Mounjaro and Zepbound.

Your gut makes natural hormones that tell your brain you are full. Tirzepatide copies two of those hormones at the same time. They are called and . It turns up that "I am full" signal. So you feel hungry less often, you eat less, and you lose weight.

It is . That means the U.S. government checked it in large studies and agreed it is safe and that it works.

What people use it for.

Most people take tirzepatide to lose weight.

Doctors also give it to people with type 2 diabetes, because it helps keep blood sugar down.

It is not a recovery or anti-aging . If that is what you are after, this is not the one.

Does it actually work?

Yes. This is one of the best-studied weight-loss drugs we have.

In the biggest study (called SURMOUNT-1), people lost about 22.5% of their body weight in about a year and a half on the top dose. That is the largest weight loss ever seen in a big trial like this. For someone who weighs 250 pounds, that is around 56 pounds.

One honest catch: the weight comes back if you stop. When people quit, a lot of the weight returns. Most people who do well either stay on it long-term, or come off slowly with a real plan.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

Tirzepatide is the strongest weight-loss drug there is.

mostly true

Honestly, close to true. In the big trial people lost about 22.5% of their body weight, the largest ever recorded in a study like that. The only catch is the next claim on this list.

Lose the weight, then stop and keep it off.

no

The weight usually comes back when you stop. It quiets your hunger, it does not reset it for good. People who keep the result either stay on a low dose or taper off slowly with a real plan.

It's the easy way out for people who won't just diet.

myth

It works on the biology of hunger, not willpower. People who had failed diets for years suddenly succeeded because the 'I am full' signal got turned up. That is medicine doing a job, not a character flaw.

Research-only tirz is the same as Mounjaro, way cheaper.

not quite

The molecule can be the same, but a vial is only as good as the seller. Stay away from 'tirzepatide + B12' or 'blend' vials, a common way to water it down, and ask for a . Only the brand is guaranteed to be what it says.

It wrecks your stomach and you stay sick the whole time.

overblown

The nausea and gut stuff are real, but they are usually worst right after you raise the dose, and they ease over time. Smaller meals and going up the ladder slowly help a lot.

How you take it.

You take it as a small shot under the skin once a week. This kind of shot is called a shot. People usually do it in the belly, the thigh, or the upper arm.

You start at a low dose and go up slowly. Going up slowly is called . Starting low gives your stomach time to get used to it, so you feel less sick.

The usual ladder is 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, moving up about every 4 weeks.

15 mg is the top of the ladder, not the start. Lots of people lose plenty of weight without ever reaching the top. If a dose is working and you feel fine, there is no rush to climb higher.

What to watch out for.

The common stuff

Most side effects are stomach problems: feeling sick (nausea), throwing up, diarrhea, or being backed up (constipation). They are usually worst right after you go up a dose, and they ease over time. Smaller meals and going up slowly help a lot.

The serious stuff

  • It carries the FDA's strongest warning (a "black box") for a rare thyroid cancer. Do not use it if you or a close family member has had this cancer, or a condition called MEN-2.
  • Birth control pills may not work as well after you raise your dose. Use a backup method (like condoms) for 4 weeks after each dose bump.
  • Losing weight fast can mean losing muscle too. To protect your muscle, eat plenty of protein and do some strength exercise while you are on it.

If anything feels wrong, talk to a real doctor. We are not your doctor.

Where people get it.

There are a few ways people get tirzepatide. Here they are from safest to riskiest.

  • Brand (Mounjaro / Zepbound). A real pharmacy product you get with a prescription. Safest. Lilly's own service (LillyDirect) sells cash vials for about $300–$450 a month.
  • . Made by special pharmacies. This used to be a cheaper middle option, but most of the big ones were shut down in 2025, so it is getting hard to find.
  • Research-only () or the . Cheap, but sold "for research only," with no promise of what is really in the vial. You mix it yourself. This is the highest risk.

One scam to know about: stay away from vials labeled "tirzepatide + B12" or "tirzepatide blend." That mix is a common way sellers water down the real drug, so you get less than you paid for. The cleanest product is tirzepatide on its own. If you buy from a research vendor, ask for a , a lab report that shows what is really in the vial.

Our honest take.

This is the real deal
Tirzepatide put up the biggest weight-loss number any drug has ever managed in a serious trial: about 22.5% of body weight. Picture someone at 220 walking out near 170, roughly 50 pounds gone. It is , it is not a gamble, and it works.

The one honest catch: it works while you are on it. Stop cold and the hunger comes back, and usually the weight with it. It quiets your appetite, it does not rewire it. So the real question was never whether it works. It is two questions: are you ready to run it for the long haul, and can you get it from a clean source. Sort those out and this is about as close to a sure thing as peptides get.

One move that pays off the whole time: eat real protein and lift something heavy. You will lose fat either way. This is how you make sure you do not lose the muscle with it.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

  1. 01Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870.
  2. 02Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England journal of medicine. 2021;385(6):503-515. PMID: 34170647.
  3. 03Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England journal of medicine. 2025;392(10):958-971. PMID: 39536238.
  4. 04Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England). 2023;402(10402):613-626. PMID: 37385275.
  5. 05Zhao L, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024;332(7):551-560. PMID: 38819983.
  6. 06France NL, et al. Tirzepatide: A Review in Type 2 Diabetes. Drugs. 2024;84(2):227-238. PMID: 38388874.
  7. 07Dahl D, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-545. PMID: 35133415.
  8. 08Nicholls SJ, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. American heart journal. 2024;267:1-11. PMID: 37758044.
  9. 09Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England journal of medicine. 2024;391(13):1193-1205. PMID: 38912654.
  10. 10Nauck MA, et al. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular diabetology. 2022;21(1):169. PMID: 36050763.
  11. 11Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine. 2025;392(5):427-437. PMID: 39555826.
  12. 12Rodriguez PJ, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA internal medicine. 2024;184(9):1056-1064. PMID: 38976257.
  13. 13Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2021;398(10295):143-155. PMID: 34186022.
  14. 14Loomba R, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. The New England journal of medicine. 2024;391(4):299-310. PMID: 38856224.
  15. 15Sattar N, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature medicine. 2022;28(3):591-598. PMID: 35210595.
  16. 16Karagiannis T, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024;67(7):1206-1222. PMID: 38613667.
  17. 17Heise T, et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes care. 2023;46(5):998-1004. PMID: 36857477.
  18. 18Gettman L. New Drug: Tirzepatide (Mounjaro(™)). The Senior care pharmacist. 2023;38(2):50-62. PMID: 36751934.
  19. 19Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight. 2020;5(17). PMID: 32730231.
  20. 20Rosenstock J, et al. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA. 2023;330(17):1631-1640. PMID: 37786396.
  21. 21Skelley JW, et al. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. Journal of the American Pharmacists Association : JAPhA. 2024;64(1):204-211.e4. PMID: 37940101.
  22. 22Del Prato S, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet (London, England). 2021;398(10313):1811-1824. PMID: 34672967.
  23. 23Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, obesity & metabolism. 2025;27(5):2720-2729. PMID: 39996356.
  24. 24Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England journal of medicine. 2025;393(1):26-36. PMID: 40353578.
  25. 25Ravussin E, et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell metabolism. 2025;37(5):1060-1074.e4. PMID: 40203836.
  26. 26Karagiannis T, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251-1261. PMID: 35579691.
  27. 27Gastaldelli A, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. The lancet. Diabetes & endocrinology. 2022;10(6):393-406. PMID: 35468325.
  28. 28Heerspink HJL, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. The lancet. Diabetes & endocrinology. 2022;10(11):774-785. PMID: 36152639.
  29. 29Sumithran P, et al. Cardiovascular effects of tirzepatide. The Journal of endocrinology. 2025;264(2). PMID: 39751188.
  30. 30Tan B, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. International journal of obesity (2005). 2023;47(8):677-685. PMID: 37253796.
  31. 31Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in endocrinology. 2023;14:1214334. PMID: 37908750.
  32. 32Samms RJ, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. The Journal of clinical investigation. 2021;131(12). PMID: 34003802.
  33. 33Inagaki N, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. The lancet. Diabetes & endocrinology. 2022;10(9):623-633. PMID: 35914543.
  34. 34Cai W, et al. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Frontiers in public health. 2024;12:1277113. PMID: 38356942.
  35. 35Krüger N, et al. Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction. JAMA. 2025;334(14):1255-1266. PMID: 40886075.
  36. 36Masson W, et al. Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Reviews in endocrine & metabolic disorders. 2026;27(1):5-15. PMID: 41032183.
  37. 37Syed YY. Tirzepatide: First Approval. Drugs. 2022;82(11):1213-1220. PMID: 35830001.
  38. 38Regmi A, et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell metabolism. 2024;36(7):1534-1549.e7. PMID: 38878772.
  39. 39Kadowaki T, et al. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. The lancet. Diabetes & endocrinology. 2025;13(5):384-396. PMID: 40031941.
  40. 40Hannon TS, et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2025;406(10511):1484-1496. PMID: 40975112.
  41. 41Thomas MK, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. The Journal of clinical endocrinology and metabolism. 2021;106(2):388-396. PMID: 33236115.
  42. 42Qin W, et al. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine. 2024;86(1):70-84. PMID: 38850440.
  43. 43Sattar N, et al. Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence. Diabetes, obesity & metabolism. 2025;27(10):5386-5392. PMID: 40555920.
  44. 44Heise T, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. The lancet. Diabetes & endocrinology. 2022;10(6):418-429. PMID: 35468322.
  45. 45Corrao S, et al. Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence. Frontiers in endocrinology. 2024;15:1402583. PMID: 38978621.
  46. 46Wen J, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinology, diabetes & metabolism. 2025;8(3):e70045. PMID: 40184508.
  47. 47Chuang MH, et al. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes. JAMA network open. 2024;7(8):e2427258. PMID: 39133485.
  48. 48Ludvik B, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet (London, England). 2021;398(10300):583-598. PMID: 34370970.
  49. 49Kanbay M, et al. Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials. Diabetes, obesity & metabolism. 2023;25(12):3766-3778. PMID: 37700437.
  50. 50Sokary S, et al. The promise of tirzepatide: A narrative review of metabolic benefits. Primary care diabetes. 2025;19(3):229-237. PMID: 40221292.
  51. 51Schneck K, et al. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: pharmacometrics & systems pharmacology. 2024;13(3):494-503. PMID: 38356317.
  52. 52Zile MR, et al. Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity. Circulation. 2025;151(10):656-668. PMID: 39556714.
  53. 53Billings LK, et al. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. Annals of internal medicine. 2025;178(5):609-619. PMID: 40183678.
  54. 54Mondoh A, et al. Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape. Expert opinion on pharmacotherapy. 2025;26(17):1841-1854. PMID: 41351384.
  55. 55Lin F, et al. Weight loss efficiency and safety of tirzepatide: A Systematic review. PloS one. 2023;18(5):e0285197. PMID: 37141329.
  56. 56O'Keefe JH, et al. Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy. Progress in cardiovascular diseases. 2025;89:102-112. PMID: 39743126.
  57. 57Taktaz F, et al. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide. Cardiovascular diabetology. 2024;23(1):242. PMID: 38987789.
  58. 58Venniyoor A. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. 2022;387(15):1433-1434. PMID: 36239654.
  59. 59Franco JV, et al. Tirzepatide for adults living with obesity. The Cochrane database of systematic reviews. 2025;10(10):CD016018. PMID: 41161687.
  60. 60Wilson L, et al. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER). Diabetes, obesity & metabolism. 2026;28(3):2403-2415. PMID: 41491349.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.